ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Temporal trends in healthcare resource use and costs of chronic kidney disease in a Spanish population: the REDIC study.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesThis study aimed to assess 10-year trends in healthcare resource utilization (HCRU) and associated direct and indirect costs related to chronic kidney disease (CKD) from both a societal and payer (CatSalut) perspectives in Catalonia, Spain.
methodsRetrospective, population-based cohort study including 447,202 newly diagnosed CKD cases from the SIDIAP database between 2012 and 2022. HCRU and costs were analyzed annually using a bottom-up, prevalence-based approach and reported per 1,000 patient-years. Data sources included primary care (PC), hospital admissions, and national cost databases.
resultsOver the 10-year study period, drug treatments and outpatient visits consistently accounted for the largest share of HCRU. Between 2014 and 2021, total CKD-related costs rose from €3.66 million to €4.61 million, representing a 26% increase. Hospitalizations consistently accounted for over 50% of total costs, with CKD-specific hospitalization costs increasing notably after 2017. Visit-related costs were the second-largest expenditure, declining from 25.2% of total costs in 2014 to 18.2% in 2021, with PC visits remaining the dominant outpatient category. Expenditures related to kidney replacement therapy increased substantially, rising from €144,188 in 2014 to €370,111 in 2021, a 157% rise, primarily driven by dialysis. Indirect costs associated with sick leave nearly doubled, rising from €324,770 in 2014 to €680,672 in 2021, representing a 110% increase.
conclusionsCKD-related hospitalizations were a significant cost driver in Catalonia. Enhancing early detection, reinforcing PC capacity, and optimizing outpatient management could help reduce costly hospital dependence and address the rising clinical and economic burden of CKD in regional health systems.
Indexed as
Identifiers
42154360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.